CurrentBlue Cross Blue Shield - IowaPolicy 05.04.65

Disposable Insulin Pumps and Automated Insulin Delivery Systems

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Iowa Policy 05.04.65 alerts

Get alerted when Policy 05.04.65 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs prior authorization, coverage criteria, and quantity limits for disposable and tubed insulin pumps and automated insulin delivery (AID) systems (Omnipod family and Twiist) for Wellmark Blue Cross and Blue Shield members.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyDisposable Insulin Pumps and Automated Insulin Delivery Systems

Policy CodePolicy 05.04.65

Change TypeNo material changes

Effective DateMay 22, 2026

Last ReviewApr 1, 2026

Next Review Date

Key ActionObtain prior authorization and document prescription/consultation with an endocrinologist or CDCES-certified provider plus required clinical documentation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

10 / 30dstandard monthly pod allowance

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - IowaPolicy 05.04.65

Disposable Insulin Pumps and Automated Insulin Delivery Systems

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Iowa Policy 05.04.65 alerts

Get alerted when Policy 05.04.65 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyDisposable Insulin Pumps and Automated Insulin Delivery Systems

Policy CodePolicy 05.04.65

Change TypeNo material changes

Effective DateMay 22, 2026

Last ReviewApr 1, 2026

Next Review Date

Key ActionObtain prior authorization and document prescription/consultation with an endocrinologist or CDCES-certified provider plus required clinical documentation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

10 / 30dstandard monthly pod allowance

30 / 30dpost-limit PA quantity

1 / 5ystarter kit allowance

300 unitsTwiist reservoir

May 22, 2026effective date

Coverage Criteria for Disposable Insulin Pumps and AID Systems

Initial Approval - Covered with prior authorization when ALL of the following are met

Covered with prior authorization when ALL of the following are met

Prescriber: Prescribed by or in consultation with an endocrinologist or a provider with Diabetes Care and Education Specialist (CDCES) certification

Prior insulin administration: Member has utilized at least one of the following for at least the last 6 months: (i) use of an insulin pump OR (ii) multiple daily insulin injections with at least 3 daily injections (basal and bolus) AND history of suboptimal blood sugar control6 months

Examples of suboptimal control include repeated hypoglycemic events (BG < 70 mg/dL), diabetic ketoacidosis, wide blood glucose fluctuations, hypoglycemia unawareness, HbA1c ≥ 7.0, or 'dawn phenomenon' with fasting BG repeatedly > 200 mg/dL

Monitoring: Member has monitored blood glucose ≥ 4 times per day OR has used a continuous glucose monitor (CGM) for at least the last 6 months>=4 times/day or CGM 6 months

Education: Member or caregiver has completed physician-directed comprehensive diabetes management education

Quantity limit: Quantity does not exceed 10 per month<=10/month

Omnipod: additional pods may be approved if member requires >200 units of insulin every 3 days; Twiist: additional cassettes may be approved if member requires >300 units of insulin every 3 days

Continuation of Therapy - Ongoing coverage will be approved if ALL of the following are met

Ongoing coverage will be approved if ALL of the following are met

Clinical benefit: Member is experiencing clinical benefit (e.g., improved glucose control, better adherence to therapy)

Continued eligibility: Member continues to meet the Initial Approval criteria

Refer to Initial Approval criteria: prescriber, prior insulin administration, monitoring, education, and quantity limits

The Omnipod DASH Intro Kit is not covered under the standard benefit allowance; the policy lists the Intro Kit as Not Covered for the DASH product line. For starter/controller devices (starter kits) the policy treats the personal diabetes manager (PDM) as a non-disposable component: a starter kit is only provided when the member is initiating therapy or when replacement is required due to manufacturer warranty expiration. The standard allowance for Omnipod starter kits is 1 kit / 5 years for Omnipod 5 and Omnipod starter kit rules apply as noted.

No additional coverage criteria or explicit exclusions are stated in this section of the document. The policy indicates reporting of provider services using appropriate CPT, HCPCS, revenue, and ICD codes but does not add further coverage rules here.

Replacement personal diabetes manager (PDM) controllers are considered non-disposable; the starter kit (which includes the PDM and accessories) should only be supplied at therapy initiation or when replacement is necessary because the manufacturer warranty has expired. The policy sets a starter/intro kit allowance of 1 kit / 5 years for starter kits where applicable.

There are no explicit statements in this portion of the policy declaring items or services to be 'not medically necessary.' The document instead focuses on quantity limits and billing/reporting instructions without listing additional 'not medically necessary' language in this section.

Billing, Codes, and Quantity Thresholds

Provider billing codesmixed

No codes listed

Procedures and billing codesmixed

No codes listed

Insulin usage thresholds for additional supplies — Omnipod and Twiist

Omnipod additional supply threshold>200 units of insulin every 3 days may qualify member for additional Omnipod pods beyond the standard 10 pods/30 days

Twiist additional supply threshold>300 units of insulin every 3 days may qualify member for additional Twiist cassettes beyond the standard quantity limit

Standard monthly quantity limit (context)Quantity does not exceed 10 per month for Omnipod/Omnipod 5 pods under standard benefit allowance

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior authorization required for Omnipod and Twiist

Omnipod and Twiist insulin delivery systems require prior authorization and are covered only when all listed clinical and administrative criteria are met, including prescriber qualifications, prior insulin administration history, monitoring, education, and quantity limits.

Coverage granted only when all Initial Approval criteria are satisfied (see criteria list).
Quantity limits apply (standard = 10 pods/30 days; exceptions detailed for high insulin use).

Billing Rule

Report provider services with appropriate CPT/HCPCS/ICD codes

Report provider services using the appropriate procedure and diagnosis codes as applicable; the policy directs use of CPT, HCPCS (alpha‑numeric), revenue, and ICD diagnostic codes for reporting.

Background and Scope

Automated insulin delivery (AID) systems integrate three components: an insulin pump, a continuous glucose monitor (CGM), and a control algorithm that modulates insulin delivery based on CGM feedback and predicted glucose trends. These systems (sometimes called hybrid closed-loop systems) combine continuous subcutaneous insulin infusion (CSII) technology with sensor-driven algorithms to adjust basal and bolus dosing. The American Diabetes Association prefers AID systems for many people with insulin-deficient diabetes because they can improve glycated hemoglobin (A1c) and increase time in range while reducing hypoglycemia risk compared with less automated intensive insulin regimens.

Key Definitions

AID system definition

DefinitionAutomated insulin delivery (AID) system integrates an insulin pump, a continuous glucose monitoring (CGM) system, and an algorithm that determines and adjusts insulin delivery based on CGM feedback and predicted glucose trends

MechanismAdjusts insulin by modulating basal rates or delivering microboluses/microdoses every ~5 minutes based on glucose level and rate of change

Operational noteAID systems provide automated correction doses but still require manual carbohydrate entry for prandial dosing

CSII definition

DefinitionContinuous subcutaneous insulin infusion (CSII) refers to traditional insulin pumps that deliver rapid-acting insulin continuously at a steady basal rate and allow bolus doses for meals and corrections

Purpose

Policy Revision History

2026-05-22Policy effective dateLatest

Policy became effective May 22, 2026.

2026-04Reviewed and revised

Policy reviewed and revised April 2026 (document notes most recent review/revision April 2026).

2026-03Reference update

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyDisposable Insulin Pumps and Automated Insulin Delivery Systems

Policy CodePolicy 05.04.65

Change TypeNo material changes

Effective DateMay 22, 2026

Last ReviewApr 1, 2026

Next Review Date

Key ActionObtain prior authorization and document prescription/consultation with an endocrinologist or CDCES-certified provider plus required clinical documentation.

SourceLink

On This Page

Use appropriate CPT and/or HCPCS codes and relevant ICD diagnosis codes when submitting provider service claims.
No device‑specific CPT/HCPCS codes are listed in the policy — include applicable codes for professional services rendered.

Step Therapy

Step/previous therapy: prior pump or MDI use ≥6 months with SMBG/CGM evidence

Members must have used an insulin pump OR multiple daily injections for at least 6 months (with ≥3 daily injections) and have documented frequent SMBG (≥4/day) or CGM use as part of eligibility for approval.

Multiple daily injections requirement: at least 3 injections per day for ≥6 months with history of suboptimal control (examples provided).
Alternatively, prior pump use for ≥6 months qualifies; monitoring requirement: SMBG ≥4 times/day or CGM use for the specified duration.

Note

Provider instruction: follow prescriber, monitoring, and education requirements

Providers must ensure all prior authorization documentation requirements are submitted; if any other provider‑facing instruction appears in the policy, follow the listed prescriber, monitoring, and education documentation rules.

Confirm prescriber is endocrinologist or in consultation with one, or provider has CDCES certification.
Verify completion of physician‑directed comprehensive diabetes education and device training as applicable.

Documentation Required

Required documentation for prior authorization

Prior authorization submissions must include documentation of prescriber qualifications/consultation, prior insulin therapy method and duration, monitoring frequency (SMBG or CGM), and completion of diabetes management education.

Document prescription by or consultation with an endocrinologist or a CDCES‑certified provider.
Document prior insulin administration method for at least 6 months (pump or MDI with ≥3 daily injections) and examples of suboptimal control if applicable.
Document SMBG frequency (≥4/day) or CGM use duration and completion of physician‑directed diabetes education.

Billing Rule

Reporting requirement: use appropriate CPT/HCPCS/revenue/ICD codes

When reporting provider services, use appropriate CPT, HCPCS (alpha‑numeric), revenue, and ICD diagnostic codes as applicable; the policy explicitly directs use of these code types.

Include CPT/HCPCS and ICD codes that correspond to the professional services provided when submitting claims.
Policy lists code types to use but provides N/A for specific codes — ensure applicable codes are selected from standard coding resources.

Denial Risk

Denial risk if prior authorization not obtained

Failure to obtain required prior authorization for Omnipod or Twiist may result in noncoverage; coverage is contingent on meeting all listed criteria and quantity limits.

Claims for devices without an approved prior authorization are at risk of denial or noncoverage.
Quantity limits (standard and post‑limit exceptions) apply and must be justified in the authorization.

Note

Coding omission risk: no specific CPT/HCPCS codes listed

The policy does not list specific CPT or HCPCS codes for provider services; omission of appropriate service codes when billing may trigger denials or processing issues.

No device‑specific CPT/HCPCS codes are provided in the policy's coding section (listed as N/A).
Ensure professional services are billed with correct, supported codes to avoid denials due to coding omission.

Used to manage blood glucose by providing basal insulin and bolus doses around mealtimes and for hyperglycemia corrections

Candidate characteristicsIdeal candidates perform multiple daily injections and at least 4 SMBG checks daily or use CGM and are motivated to achieve glucose control

510(k) device reference

510(k) reference — OmnipodOmnipod 510(k) Premarket Notification listed in FDA Home Medical Devices Databases (K192659) — see FDA 510(k) documentation

510(k) reference — TwiistTwiist System 510(k) Premarket Notification listed in FDA Home Medical Devices Databases (K250930)

Purpose of referencesFDA 510(k) Premarket Notification documents provide regulatory clearance details for specific disposable insulin pump systems

Omnipod 510(k) reference accessed March 2026 and added to references.

2025-06-16Reference access

Twiist 510(k) reference accessed June 16, 2025 and included in references.